Table 3.
Mice | Rat | Pig | |
---|---|---|---|
Advantages | High reproductive rate Genetically modifiable Commercially available tools (existing antibodies, primers) Postnatal intestinal development Ability to induce NEC at various ages |
High reproductive rate Relatively larger size than mouse Easier to gavage feed than mice Neonatal rats more resilient than mice |
Preterm viability Ability to evaluate perfusion/hemodynamics Can perform sequential lab work Ability to mimic identical feeding practices (formula, TPN) and clinical exposure Similar GI physiology/size to human neonates |
Limitations | Difficult to gavage feed Require regular feeds for hydration and glucose regulation |
Lack of transgenic lines High endotoxin/bacterial tolerance Requires c-section to avoid dam milk |
Limited molecular diagnostic tools Can develop global intestinal injury |
Cost | Low | Low | High |
Ideal for: | Elucidating mechanisms, pathways and single gene effects driving pathogenesis | Testing safety/feasibility Temporal biomarker studies |
Translational evaluation for therapeutic strategies |
Models: | HF, HHF, ABT, PCD, PIA, I/R, MHK, FF | HF, HHF, I/R | HHF, ABT, I/R, FF, FF/PN |
HHF, hypoxia-hypothermia-formula feeding; ABT, antibiotic exposure; PCD, Paneth cell disruption; PIA, phlebotomy-induced anemia; I/R, Ischemia/reperfusion; MHK, Maltodextrin ± hypoxia ± Klebsiella; FF, formula feeding; PN + FF, parenteral nutrition followed by formula.